Peyronie's disease (PD) is accompanied by remodelling of connective tissue into fibrotic plaque. Treatment of the inflammatory and fibrotic phases of the disease is not established. The aim of the study was to evaluate the effect of verapamil (VER) and bacterial collagenase (COLL) on collagen metabolism and cell migration in fibroblasts with experimental wound healing and inflammation as an in vitro model of PD.
In vitro model of PD was designed using experimental model of inflammation induced by Interleukin-1 (IL-1) in cultured fibroblasts and mechanical damage of the cells. Cell viability, cell proliferation, collagen biosynthesis, prolidase activity and cell migration were studied in both models of the cells treated with VER and COLL.
VER decreased cell viability, DNA and collagen biosynthesis and increased prolidase activity in control fibroblast, while in "wounded" fibroblasts it significantly decreased all the processes. COLL did not affect cell viability and DNA biosynthesis, while inhibited collagen biosynthesis and prolidase activity in both control and "wounded" fibroblasts. In IL-1-treated fibroblasts VER inhibited all studied processes except prolidase activity, while COLL inhibited only collagen biosynthesis and prolidase activity. COLL accelerated cell migration, while VER attenuated the process in fibroblast model of wound healing, compared to control cells.
VER and COLL attenuate collagen biosynthesis in both fibroblast models. The VER-dependent inhibition of collagen biosynthesis was accompanied by inhibition of DNA biosynthesis at high prolidase activity, while COLL affected this process through inhibition of prolidase activity at high rate of DNA biosynthesis. It shows that anti-fibrotic activity of VER/COLL and anti-inflammatory activity of VER may represent approach to establish standard treatment of PD.
Molecular and cellular probes. 2019 Nov 13 [Epub ahead of print]
Jacek Karaszewski, Ilona Zareba, Tomasz Guszczyn, Barbara Darewicz, Jerzy Palka
Department of Urology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276, Białystok, Poland. Electronic address: ., Department of Medicinal Chemistry, Medical University of Bialystok, Adama Mickiewicza 2D, 15-222, Bialystok, Poland. Electronic address: ., Department of Paediatric Orthopaedics and Traumatology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276, Bialystok, Poland. Electronic address: ., Department of Urology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276, Białystok, Poland. Electronic address: ., Department of Medicinal Chemistry, Medical University of Bialystok, Adama Mickiewicza 2D, 15-222, Bialystok, Poland. Electronic address: .